241 related articles for article (PubMed ID: 32297534)
1. Engineering vaccinia virus as an immunotherapeutic battleship to overcome tumor heterogeneity.
Pelin A; Boulton S; Tamming LA; Bell JC; Singaravelu R
Expert Opin Biol Ther; 2020 Sep; 20(9):1083-1097. PubMed ID: 32297534
[TBL] [Abstract][Full Text] [Related]
2. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy.
Shi Z; Liu B; Huang C; Xie W; Cen Y; Chen L; Liang M
Biochem Biophys Res Commun; 2021 Jun; 559():176-182. PubMed ID: 33945995
[TBL] [Abstract][Full Text] [Related]
3. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic vaccinia virus immunotherapy antagonizes image-guided radiotherapy in mouse mammary tumor models.
Umer BA; Noyce RS; Kieser Q; Favis NA; Shenouda MM; Rans KJ; Middleton J; Hitt MM; Evans DH
PLoS One; 2024; 19(3):e0298437. PubMed ID: 38498459
[TBL] [Abstract][Full Text] [Related]
5. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
[TBL] [Abstract][Full Text] [Related]
6. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.
Kochneva G; Sivolobova G; Tkacheva A; Grazhdantseva A; Troitskaya O; Nushtaeva A; Tkachenko A; Kuligina E; Richter V; Koval O
Oncotarget; 2016 Nov; 7(45):74171-74188. PubMed ID: 27708236
[TBL] [Abstract][Full Text] [Related]
7. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
[TBL] [Abstract][Full Text] [Related]
8. Deciphering the Immunomodulatory Capacity of Oncolytic Vaccinia Virus to Enhance the Immune Response to Breast Cancer.
Umer BA; Noyce RS; Franczak BC; Shenouda MM; Kelly RG; Favis NA; Desaulniers M; Baldwin TA; Hitt MM; Evans DH
Cancer Immunol Res; 2020 May; 8(5):618-631. PubMed ID: 32127390
[TBL] [Abstract][Full Text] [Related]
9. Arming oncolytic viruses to leverage antitumor immunity.
de Gruijl TD; Janssen AB; van Beusechem VW
Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic vaccinia virus and cancer immunotherapy.
Xu L; Sun H; Lemoine NR; Xuan Y; Wang P
Front Immunol; 2023; 14():1324744. PubMed ID: 38283361
[TBL] [Abstract][Full Text] [Related]
11. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them.
Hu PY; Fan XM; Zhang YN; Wang SB; Wan WJ; Pan HY; Mou XZ
Appl Microbiol Biotechnol; 2020 Oct; 104(19):8231-8242. PubMed ID: 32816087
[TBL] [Abstract][Full Text] [Related]
12. Poxvirus oncolytic virotherapy.
Torres-Domínguez LE; McFadden G
Expert Opin Biol Ther; 2019 Jun; 19(6):561-573. PubMed ID: 30919708
[TBL] [Abstract][Full Text] [Related]
13. Design Strategies and Precautions for Using Vaccinia Virus in Tumor Virotherapy.
Liu X; Zhao J; Li X; Lao F; Fang M
Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146629
[TBL] [Abstract][Full Text] [Related]
14. Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers.
Draganov DD; Santidrian AF; Minev I; Nguyen D; Kilinc MO; Petrov I; Vyalkova A; Lander E; Berman M; Minev B; Szalay AA
J Transl Med; 2019 Mar; 17(1):100. PubMed ID: 30917829
[TBL] [Abstract][Full Text] [Related]
15. The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy.
de Vries CR; Monken CE; Lattime EC
Cancer Gene Ther; 2015 Apr; 22(3):154-62. PubMed ID: 25633483
[TBL] [Abstract][Full Text] [Related]
16. CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging.
Parviainen S; Ahonen M; Diaconu I; Hirvinen M; Karttunen Å; Vähä-Koskela M; Hemminki A; Cerullo V
Gene Ther; 2014 Feb; 21(2):195-204. PubMed ID: 24305418
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
Russell L; Peng KW; Russell SJ; Diaz RM
BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
[TBL] [Abstract][Full Text] [Related]
18. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.
Guo ZS; Lu B; Guo Z; Giehl E; Feist M; Dai E; Liu W; Storkus WJ; He Y; Liu Z; Bartlett DL
J Immunother Cancer; 2019 Jan; 7(1):6. PubMed ID: 30626434
[TBL] [Abstract][Full Text] [Related]
19. Clinical development directions in oncolytic viral therapy.
Eager RM; Nemunaitis J
Cancer Gene Ther; 2011 May; 18(5):305-17. PubMed ID: 21436867
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic viruses for cancer immunotherapy.
Hemminki O; Dos Santos JM; Hemminki A
J Hematol Oncol; 2020 Jun; 13(1):84. PubMed ID: 32600470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
